Search results
Showing 691 to 705 of 1809 results for nice guidelines
We want you to tell us what matters to you, your organisation or your community.
individual. Making sure workers in adult social care get the best out of NICE guidelines and quality standards is about framing guidance...
Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)
Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making
Improving young people's experiences in transition to and from inpatient mental health settings
A quick guide for mental health practitioners supporting young people transitioning to and from inpatient mental health settings
We estimate the costs or savings (budget impact) associated with technologies and guidelines so you can plan for and implement guidance.
Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making
This indicator covers the percentage of patients with diabetes and a history of cardiovascular disease (excluding a history of haemorrhagic stroke) who are currently treated with a statin. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM163
This indicator covers the percentage of mothers who give their babies breast milk in the first 48 hours after delivery. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG33
2018 we published the NICEimpact report on maternity. This considered how NICE's evidence-based guidance might contribute to...
Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction.
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
This indicator covers, in patients aged between 25 and 84 years, with a new diagnosis of hypertension or type 2 diabetes recorded in the preceding 12 months (excluding those with pre-existing cardiovascular disease, chronic kidney disease, familial hypercholesterolaemia or type 1 diabetes), who have a recorded cardiovascular risk assessment score of more than 20% in the preceding 12 months, the percentage who are currently treated with statins (unless there is a contraindication). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM133
Weight management: BMI recording (long-term conditions) (IND151)
This indicator covers the percentage of patients with coronary heart disease, stroke or TIA, diabetes, hypertension, peripheral arterial disease, heart failure, COPD, asthma and/or rheumatoid arthritis who have had a BMI recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM121
Hip fracture: surgery on the day or day after admission (IND14)
This indicator covers the proportion of people with hip fracture, who receive surgery on the day of, or the day after, admission. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG21
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.